Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS11D | O60235 | 11/20 | 0.52 |
| ▸ | F2 | P00734 | 4/20 | 0.52 |
| ▸ | F10 | P00742 | 4/20 | 0.52 |
| ▸ | PLG | P00747 | 3/20 | 0.52 |
| ▸ | ACE | P12821 | 3/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12968487 | 0.90 | TMPRSS11D (0.53) | TMPRSS11DF2F10PLGACE | |
| SCHEMBL10058303 | 0.90 | TMPRSS11D (0.55) | TMPRSS11DF2F10PLGACE | |
| SCHEMBL10058135 | 0.87 | TMPRSS11D (0.51) | TMPRSS11DF2F10PLGACE | |
| SCHEMBL15139664 | 0.81 | ACE (0.51) | TMPRSS11DF2F10PLGACE | |
| SCHEMBL15139686 | 0.81 | TMPRSS11D (0.50) | TMPRSS11DF2F10PLGACE | |
| SCHEMBL12968535 | 0.81 | ALDH1A1 (0.60) | ACEALDH1A1ACE2ITGB3ITGA2B | |
| SCHEMBL19390410 | 0.80 | TMPRSS11D (0.50) | TMPRSS11DF2F10PLGACE | |
| SCHEMBL19390241 | 0.80 | ACE (0.53) | TMPRSS11DACELMNAACE2 | |
| SCHEMBL12968410 | 0.80 | TMPRSS11D (0.59) | TMPRSS11DF2F10PLGACE | |
| SCHEMBL15251707 | 0.79 | FKBP1A (0.52) | TMPRSS11DF2F10PLGACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655399-B1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-8497245-B2 | Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors IIa and Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20120252743-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2012083436-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252743-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | F2, F12, SERPINC1 | TMPRSS11D 49/4885F2 1/4885F10 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.